KIR3DL1 and acute myeloid leukemia: Similar results were observed by Boudreau et al. 29 when investigated the impact of KIR3DL1/HLA-B combinations in 1,328 patients with acute myelogenous leukemia who underwent hematopoietic cell transplantation (HCT).